Compare MEI & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEI | XFOR |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | 407.5M |
| IPO Year | 1994 | N/A |
| Metric | MEI | XFOR |
|---|---|---|
| Price | $12.02 | $4.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.00 | $9.00 |
| AVG Volume (30 Days) | ★ 739.3K | 360.5K |
| Earning Date | 03-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 49.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $908,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $4.88 | $1.35 |
| 52 Week High | $15.55 | $4.83 |
| Indicator | MEI | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 58.29 | 49.83 |
| Support Level | $6.70 | $3.97 |
| Resistance Level | $13.53 | $4.09 |
| Average True Range (ATR) | 0.83 | 0.22 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 54.04 | 46.43 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.